中医药调控NLRP3炎症小体干预尿酸性肾病的研究进展OA
Research progress on the regulation of NLRP3 inflammasome by traditional Chinese medicine in the intervention of uric acid nephropathy
尿酸性肾病(UAN)作为高尿酸血症(HUA)常见的肾脏继发病变,其发病机制与 NOD 样受体蛋白 3(NLRP3)炎症小体激活介导的炎症应答密切相关.尿酸(UA)可通过诱导线粒体活性氧(ROS)产生、引发内质网应激、促进钾离子外流以及激活 Toll 样受体 4(TLR4)/核因子-κB(NF-κB)信号通路等多种机制,使 NLRP3炎症小体活化,进而促进白细胞介素-1β(IL-1β)、白细胞介素-18(IL-18)等炎症因子释放,最终引起肾小管上皮细胞损伤与肾脏间质纤维化.中医药在干预 UAN 进程中展现出多靶点调控优势,已形成了从单味中药有效组分、中成药到中药复方的多层次干预体系.本文围绕上述三类中医药途径,系统梳理其在调控 NLRP3 炎症小体及其上游信号、减轻肾脏炎症反应、延缓 UAN 进展中的作用机制与研究进展,以期为中医药靶向 NLRP3 炎症小体治疗UAN 提供理论依据与研究视角.
Uric acid nephropathy(UAN),a common renal complication of hyperuricemia(HUA),is closely related to the activation of NOD-like receptor protein 3(NLRP3)inflammasome-mediated inflammatory response.Uric acid(UA)can activate the NLRP3 inflammasome through multiple mechanisms,such as inducing mitochondrial reactive oxygen species(ROS)production,triggering endoplasmic reticulum stress,promoting potassium ion efflux,and activating the Toll-like receptor 4(TLR4)/nuclear factor-κB(NF-κB)signaling pathway,thereby promoting the release of inflammatory factors such as interleukin-1β(IL-1β)and interleukin-18(IL-18),and ultimately causing renal tubular epithelial cell injury and renal interstitial fibrosis.Traditional Chinese medicine(TCM)has shown multi-target regulatory advantages in the intervention of UAN and has formed a multi-level intervention system from single-component effective parts of single herbs,Chinese patent medicines to TCM formulas.This review systematically summarize the mechanism and research progress of the above three types of TCM approaches in regulating the NLRP3 inflammasome and its upstream signals,reducing renal inflammatory responses,and delaying the progression of UAN,with the aim of providing theoretical basis and research perspectives for TCM targeting the NLRP3 inflammasome in the treatment of UAN.
王强艳;高泓
成都中医药大学附属医院,四川 成都 610072||成都中医药大学附属医院内分泌科,四川 成都 610072成都中医药大学附属医院,四川 成都 610072||成都中医药大学附属医院内分泌科,四川 成都 610072||成都中医药大学附属医院,代谢与慢病中医药防治四川省重点实验室,四川 成都 610072
医药卫生
尿酸性肾病NLRP3炎症反应中医药
Uric acid nephropathyNLRP3Inflammatory responseTraditional Chinese medicine
《四川中医》 2026 (8)
120-127,8
四川省中医药管理局科学技术研究专项重点项目(2024zd002)四川省中医药管理局科学技术研究专项面上项目(2024MS548)成都市卫生健康委员会-成都中医药大学委校联合创新基金项目(WXLH202403014).
评论